|[교과부·한국연구재단 지정 한림대학교 생명공학연구소]
◎ 제25차 생명공학연구소 정기세미나 개최 ◎
▶ 일 시 : 2016. 11. 17(목) 오전 11시
▶ 장 소 : (구)산학협력단 세미나실(12102호)
▶ 연 자 : 진석민 박사(종근당)
▶ 주 최 : 생명공학연구소(중점연구소)
▶ 강의제목 : Drug development process and case study with focus on the CKD’s neurodegenerative disease program.
Neurodegenerative diseases such as Alzheimer’s (AD) and Huntington’s disease (HD) are devastating for the patient’s families as well as patients suffering from them. So far, however, there is no disease-modifying treatment for them. For AD, the most prevalent neurodegenerative disease, the pathogenic mechanism is still elusive in spite of the tremendous efforts from all over the world by both academy and industry. In case of HD, although it is a genetic rare disease whose genetic cause is obvious but no cure is available as well. Considering that those two different diseases shares some important features, it could be possible to find a common way to treat both of them. For example, the axonal transport is down-regulated in both pathological conditions and the activity of histone deacetylase 6 (HDAC6) is up-regulated in the postmortem patient brains. Since 2013, CKD initiated a neurodegenerative program targeting HDAC6 to develop a first-in-class disease-modifying therapy for AD and HD. Today, the general review on the drug development process and the recent progress in CKD’s neurodegenerative disease program will be presented.
연사분을 초청하여 제 26차 정기세미나를 개최하오니 많은 참석 부탁드리겠습니다.